Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial.

开始日期2022-06-16

申办/合作机构

Priothera SAS

NCT01830010 / Completed临床1期

A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies

开始日期2013-06-28

申办/合作机构

Novartis Pharmaceuticals Corp.

JPRN-JapicCTI-132108 / Unknown status临床2期

Exploratory Phase II Study of KRP-203 -A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of KRP-203 in Patients with Crohn's Disease in Active Phase-

开始日期2013-05-01

申办/合作机构

KYORIN Pharmaceutical Co., Ltd.

100 项与 Mocravimod hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Mocravimod hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Mocravimod hydrochloride 相关的专利（医药）

登录后查看更多信息

项与 Mocravimod hydrochloride 相关的文献（医药）

2023-10-01·Biochemical and biophysical research communications

Multimodal action of KRP203 on phosphoinositide kinases in vitro and in cells

Article

作者: Hirota, Yoshihisa ; Takeuchi, Koh ; Boxer, Matthew B ; Shen, Min ; Simeonov, Anton ; Senda, Toshiya ; Davis, Mindy I ; Sasaki, Atsuo T ; Pragani, Rajan ; Zheng, Yuxiang ; Sumita, Kazutaka ; Sasaki, Mika ; Kofuji, Satoshi ; Ikeda, Yoshiki

Increased phosphoinositide signaling is commonly associated with cancers. While "one-drug one-target" has been a major drug discovery strategy for cancer therapy, a "one-drug multi-targets" approach for phosphoinositide enzymes has the potential to offer a new therapeutic approach. In this study, we sought a new way to target phosphoinositides metabolism. Using a high-throughput phosphatidylinositol 5-phosphate 4-kinase-alpha (PI5P4Kα) assay, we have identified that the immunosuppressor KRP203/Mocravimod induces a significant perturbation in phosphoinositide metabolism in U87MG glioblastoma cells. Despite high sequence similarity of PI5P4K and PI4K isozymes, in vitro kinase assays showed that KRP203 activates some (e.g., PI5P4Kα, PI4KIIβ) while inhibiting other phosphoinositide kinases (e.g., PI5P4Kβ, γ, PI4KIIα, class I PI3K-p110α, δ, γ). Furthermore, KRP203 enhances PI3P5K/PIKFYVE's substrate selectivity for phosphatidylinositol (PI) while preserving its selectivity for PI(3)P. At cellular levels, 3 h of KRP203 treatment induces a prominent increase of PI(3)P and moderate increase of PI(5)P, PI(3,5)P_2, and PI(3,4,5)P₃ levels in U87MG cells. Collectively, the finding of multimodal activity of KRP203 towards multi-phosphoinositide kinases may open a novel basis to modulate cellular processes, potentially leading to more effective treatments for diseases associated with phosphoinositide signaling pathways.

2023-07-01·Cellular immunology

Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation.

Article

作者: Bucher, Christoph ; Passweg, Jakob ; Tzankov, Alexandar ; Medinger, Michael ; Dertschnig, Simone

Graft-versus-leukemia (GvL) effects are critical to prevent relapses after allogeneic hematopoietic cell transplantation (allo-HCT). However, the success of allo-HCT is limited by graft-versus-host disease (GvHD). Both, CD4⁺ and CD8⁺ T cells contribute to GvHD and GvL. The sphingosine-1-phosphate receptor (S1PR) signaling plays a crucial role in lymphocyte trafficking. Mocravimod is an S1PR modulator and its administration leads to blocking lymphocyte egress from lymphoid organs. We hypothesized that this applies to the bone marrow (BM) too, and analyzed BM biopsies from the clinical study with mocravimod (phase I trial in allo-HCT patients; NCT01830010) by immunohistochemical staining for CD3, CD4, CD8, TIA1, FoxP3, PD1, T-Bet, GATA3, and ROR-γt to identify and quantify T cell subsets in situ. Allo-HCT patients without receiving mocravimod were used as controls. BM from 9 patients in the mocravimod group and 10 patients in the control group were examined. CD3⁺ T cells were found to accumulate in the BM of mocravimod-treated patients compared to controls, both on day 30 and 90 post-transplant. The effect was stronger for CD4⁺ T cells, than CD8⁺ T cells, which is in line with data from murine studies showing that CD4⁺ T cells are more sensitive to mocravimod treatment than CD8⁺ T cells. Clinically-relevant acute GvHD events (grade II-IV) were slightly lower, but comparable to controls when mocravimod was administered. Taken together, data are supportive of mocravimod's mode of action and bring additional evidence of fewer relapses for allo-HCT patients treated with S1PR modulators.

2023-01-01·Transplantation and cellular therapy

Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy

Article

作者: Schanz, Urs ; Heim, Dominik ; Bucher, Christoph ; Teshima, Takanori ; Holtick, Udo ; Dertschnig, Simone ; Passweg, Jakob ; Stylianou, Christos ; Finke, Jürgen ; Medinger, Michael ; Socié, Gérard ; Gergely, Peter ; Oehen, Stephan ; Holler, Ernst

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the sole curative option for patients with acute myelogenous leukemia. Outcomes are limited by leukemia relapse, graft-versus-host disease (GVHD), and abnormal immune reconstitution. Mocravimod (KRP203) is an oral sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod retains T cell effector function, a main differentiator to immunosuppressants. In preclinical models, mocravimod improves survival by maintaining graft-versus-leukemia (GVL) activity while reducing GVHD. In patients undergoing allo-HSCT for hematological malignancies, mocravimod is postulated to prevent GVHD by redistributing allogeneic donor T cells to lymphoid tissues while allowing a sufficient GVL effect in the lymphoid, where malignant cells usually reside. The primary objective of this study was to assess the safety and tolerability of mocravimod in patients undergoing allo-HSCT for hematologic malignancies. Secondary objectives were to determine the pharmacokinetic profiles of mocravimod and its active metabolite mocravimod-phosphate in this patient group, as well as to assess GVHD-free, relapse free survival at 6 months after the last treatment. In this 2-part, single- and 2-arm randomized, open-label trial, we evaluated the safety, tolerability, and pharmacokinetics of mocravimod in allo-HSCT recipients (ClinicalTrials.gov identifier NCT01830010). Patients received either 1 mg or 3 mg mocravimod per day on top of standard of care GVHD prophylaxis with either cyclosporine A/methotrexate or tacrolimus/methotrexate. We found that mocravimod can be safely added to standard treatment regimens in patients with hematologic malignancies requiring allo-HSCT. Mocravimod resulted in a significant reduction of circulating lymphocyte numbers and had no negative impact on engraftment and transplantation outcomes. Our results indicate that mocravimod is safe and support a larger study to investigate its efficacy in a homogeneous acute myelogenous leukemia patient population undergoing allo-HSCT.

项与 Mocravimod hydrochloride 相关的新闻（医药）

2023-11-27

·GlobeNewswire-Health Care

Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies

Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers Mocravimod is being investigated in a global registration-enabling Phase 3 trial This is the second Orphan Drug designation for mocravimod Priothera Ltd., a Phase 3 clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug designation (ODD) to mocravimod for the ‘treatment to improve outcome following hematopoietic stem cell transplantation in hematologic malignancies’. This ODD aims to potentially increase leukemia-free survival by enhancing a graft-versus-leukemia (GvL) response. Florent Gros, Co-Founder and CEO of Priothera, commented: “We are very pleased that the US FDA granted mocravimod this Orphan Drug designation. This designation emphasizes the importance of developing novel therapeutic options to improve the outcome and success of maintenance therapy following allo-HSCT in blood cancer patients. This is an important milestone as this ODD complements the first ODD granted for prevention of graft-versus-host disease. “The two ODDs highlight mocravimod’s dual mode of action which for the first time is being leveraged to improve the allo-HSCT treatment outcomes in hematological malignancies to potentially increase the leukemia free survival – graft-versus-leukemia response - while reducing tissue damage resulting from the graft-versus-host disease.” The first ODD granted for mocravimod by the US FDA was for the ‘prevention of graft-versus-host disease (GvHD)’ – see press release here. Mocravimod, a sphingosine-1-phosphate (S1P) receptor modulator, is being investigated in a pivotal global Phase 3 study - MO-TRANS (NCT05429632) - evaluating the efficacy and safety of mocravimod as an adjunctive and maintenance therapy to allo-HSCT. The study which is enrolling approximately 250 adult Acute Myeloid Leukemia (AML) patients, is ongoing in the US, Europe, Southeast Asia and Latin America. Mocravimod, which has been previously tested in multiple autoimmune indications, is being developed to enhance the curative potential of allo-HSCT. Moreover, it has shown a clinically meaningful outcome in a Phase 1b/2a study1 in patients with hematologic malignancies undergoing allo-HSCT. Mocravimod (also known as KRP203) is a synthetic, S1P receptor modulator. This novel investigational drug has been assessed in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmune indications. Promising data from a Phase 1b/2a clinical study in patients with hematological malignancies led Priothera to further develop mocravimod for the treatment of blood cancers and the improvement of CAR-T cell therapy. Mocravimod is currently being investigated as an adjunctive and maintenance treatment in a Phase 3 study for patients with AML receiving allogeneic HSCT. Allogeneic HSCT is the only potentially curative approach for AML patients, but current treatments have unacceptably high mortality and morbidity rates. Priothera leverages mocravimod’s dual mode of action to maintain the beneficial graft-versus-leukemia/lymphoma (GvL) activity, while reducing tissue damage resulting from graft-versus-host disease (GvHD), both a consequence of allo-HSCT. This novel treatment approach – mocravimod being the only S1P receptor modulator treating blood cancers – tackles a high unmet medical need and aims to improve patients’ quality of life. Priothera is leading the way in developing orally applied S1P receptor modulators for the treatment of hematological malignancies and for the improvement of CAR-T cell therapies. S1P receptor modulators are known to largely reduce egress of T cells from lymphatic tissues. Unlike immunosuppressive drugs, mocravimod does not suppress the GvL benefits in patients receiving allogeneic HSCT while inhibiting GvHD. Priothera was founded in 2020 by an experienced team of drug development experts and is headquartered in Dublin, Ireland, and with a subsidiary in Saint-Louis, France. The Company is backed by international founding investors Fountain Healthcare Partners (Dublin, Ireland), funds managed by Tekla Capital Management, LLC (Boston, Massachusetts), HealthCap (Stockholm, Sweden), EarlyBird Venture Capital (Berlin, Germany), as well as non-dilutive financing in the form of loans from the European Investment Bank under its Venture Debt Instrument and Bpifrance (Grand Est Bpifrance) in the form of a R&D innovation loan. The content above comes from the network. if any infringement, please contact us to modify.

临床2期孤儿药细胞疗法免疫疗法

2023-01-23

·PRNewswire

Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoing allogeneic Hematopoietic Cell Transplant (HCT)

Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T therapy Phase 1b/2a data has shown mocravimod is safe and well tolerated DUBLIN, Jan. 23, 2023 /PRNewswire/ -- Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod today announced that the first patients have been enrolled in the pivotal MO-TRANS global Phase 2b/3 study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant (HCT). Mocravimod, a sphingosine 1 phosphate (S1P) receptor modulator which has been previously tested in multiple autoimmune indications, is being developed to enhance the curative potential of allogeneic HCT. Mocravimod has shown a clinically relevant benefit in an early clinical study in patients with hematologic malignancies undergoing allogeneic HCT. Priothera is initiating the pivotal MO-TRANS global Phase 2b/3 study in Europe, Israel, the US and in additional Asian and Latin American countries, to assess the efficacy and safety of mocravimod as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HCT. The double-blind, placebo-controlled study assesses relapse-free and overall survival of two dose levels of mocravimod in comparison to placebo. Topline data from this study are expected in 2025. Marcos de Lima, M.D., is the Principal Investigator for the MO-TRANS global Phase 2b/3 trial. Dr. de Lima is professor of medicine at The Ohio State University College of Medicine and a hematologist-oncologist at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Prof de Lima said : "We are excited to be part of the important MO-TRANS global Phase 2b/3 study to investigate mocravimod, a potential new adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant. Maintenance therapy is fast becoming the new frontier in the treatment of AML and we are committed to bringing forth new innovative therapies to AML patients." Elisabeth Kueenburg, M.D., Chief Medical Officer at Priothera, commented: "This MO-TRANS global Phase 2b/3 study builds on pre-clinical and clinical proof of concept studies which demonstrated mocravimod's ability to improve survival outcomes for patients with hematological malignancies requiring allogeneic HCT. The mode of action has been well-established in autoimmune indications, but never in hematology. Mocravimod has the potential to be a first-in-class therapy in maintaining the graft-versus-leukemia effect, while preventing graft-versus-host disease, one of the most serious complications of allogeneic HCT. We expect this trial to deliver important clinical data supporting the registration of mocravimod in this indication." Florent Gros, Co-Founder and CEO of Priothera, said: "Having successfully enrolled the first AML patients undergoing allogeneic HCT in our MO-TRANS global study represents a significant milestone for Priothera as we believe mocravimod has the potential to address a significant unmet need. Furthermore, we anticipate a strong uptake in patient enrollment with a significant number of patients currently being identified. We look forward to seeing topline results in 2025." About mocravimod Mocravimod (also known as KRP203) is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This novel investigational drug has been assessed in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmune indications. Promising data from a Phase 1b/2a clinical study in patients with hematological malignancies led Priothera to further develop mocravimod for the treatment of blood cancers and the improvement of CAR-T cell therapy. Mocravimod is currently being investigated as an adjunctive and maintenance treatment in a Phase 2b/3 study for patients with Acute Myeloid Leukemia (AML) receiving allogeneic hematopoietic cell transplantation (HCT). Allogeneic HCT is the only potentially curative approach for AML patients, but current treatments have unacceptably high mortality and morbidity rates. Priothera leverages mocravimod's unique mode of action to maintain the beneficial graft-versus leukemia (GVL) activity, while reducing tissue damage resulting from graft-versus-host disease (GVHD), both a consequence of allogeneic HCT. This novel treatment approach – mocravimod being the only S1PR modulator treating blood cancers – tackles a high unmet medical need and aims to improve patients' quality of life. About Priothera Priothera is leading the way in developing orally applied sphingosine-1-phosphate (S1P) receptor modulators for the treatment of hematological malignancies and for the improvement of CAR-T cell therapies. S1P receptor modulators are known to largely reduce egress of T cells from lymphatic tissues. Unlike immunosuppressive drugs, mocravimod does not suppress the graft-versus-leukemia (GVL) benefits in patients receiving HCT while inhibiting graft-versus-host-disease (GVHD). Priothera was founded in 2020 by an experienced team of drug development experts and is headquartered in Dublin, Ireland, and with a subsidiary in Saint-Louis, France. The Company is backed by international founding investors Fountain Healthcare Partners (Dublin, Ireland), funds managed by Tekla Capital Management, LLC (Boston, Massachusetts), HealthCap (Stockholm, Sweden), EarlyBird Venture Capital (Berlin, Germany), as well as non-dilutive financing in the form of loans from the European Investment Bank under its Venture Debt Instrument and Bpifrance (Grand Est Bpifrance) in the form of a R&D innovation loan. For more information please visit: or follow Priothera on LinkedIn Contacts Priothera Florent Gros, CEO E: [email protected] MEDiSTRAVA Consulting Sylvie Berrebi, Sandi Greenwood, Frazer Hall E: [email protected] T: +44 (0) 203 928 6900 SOURCE Priothera

细胞疗法免疫疗法临床研究

2022-11-14

·PRNewswire

Priothera - Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy

Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation (HCT) patients Mocravimod significantly reduced circulating lymphocyte numbers and did not affect engraftment DUBLIN, Nov. 14, 2022 /PRNewswire/ -- Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, announces that positive data from the Phase 1b clinical trial evaluating mocravimod in allogeneic hematopoietic cell transplantation patients has been published in Transplantation and Cellular Therapy. The study assessed the safety and tolerability of mocravimod in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for hematological malignancies. The secondary objectives were to determine the pharmacokinetic profile of mocravimod in this patient group as well as to assess GvHD-free, relapse-free survival at 6 months after last treatment. The study found that mocravimod can safely be added to standard treatment regimens in patients with hematological malignancies requiring allo-HCT. CD4+ T cells were more sensitive to mocravimod treatment than CD8+ T cells. Mocravimod resulted in a significant reduction of circulating lymphocyte numbers and had no negative impact on engraftment and transplant outcomes. Mocravimod, a sphingosine 1 phosphate (S1P) receptor modulator which has been previously tested in multiple autoimmune indications, is being developed to enhance the curative potential of HCT. A global Phase 2b/3 study assessing the efficacy and safety of mocravimod as an adjunctive and maintenance therapy in acute myeloid leukemia (AML) patients undergoing allo-HCT is planned to start in the coming months. The trial design for this study will be published as an online abstract as part of the 2022 American Society of Hematology (ASH) conference (December 10-13th). Florent Gros, Co-Founder and CEO of Priothera, said: "The positive Phase 1b data reinforce the potential for mocravimod to improve survival outcomes for patients with hematological malignancies requiring HCT. We're looking forward to building upon this foundation with our upcoming pivotal Phase 2b/3 trial and advancing our lead asset towards its next significant milestones." Elisabeth Kueenburg, M.D., Chief Medical Officer at Priothera, commented: "Mocravimod's mode of action has already been well established in autoimmune indications, and the Phase 1b trial shows that its potential also extends to hematology. We believe mocravimod has the potential to be a first-in-class therapy in maintaining graft-versus-leukemia responses, one of the most serious complications of allogeneic HCT, while preventing graft-versus-host disease." References S. Dertschnig et al. Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy, Transplantation and Cellular Therapy. Online publication: About mocravimod Mocravimod (also known as KRP203) is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This novel investigational drug has been assessed in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmune indications. Promising data from a Phase 1b/2a clinical study in patients with hematological malignancies - commonly known as leukemias and lymphomas - led Priothera to further develop mocravimod for the treatment of blood cancers and the improvement of CAR-T cell therapy. Mocravimod is being investigated as an adjunctive and maintenance treatment in a Phase 2b/3 study for patients with Acute Myeloid Leukemia (AML) receiving allogeneic hematopoietic cell transplantation (HCT). Allogeneic HCT is the only potentially curative approach for AML patients, but current treatments have unacceptably high mortality and morbidity rates. Priothera leverages mocravimod's unique mode of action to maintain the beneficial graft-versus leukemia (GVL) activity, while reducing tissue damage resulting from graft-versus-host disease (GVHD), both a consequence of allogeneic HCT. This novel treatment approach – mocravimod being the only S1PR modulator treating blood cancers – tackles a high unmet medical need and intends to add quality life to patients. About Priothera Priothera is leading the way in developing orally applied sphingosine-1-phosphate (S1P) receptor modulators for the treatment of hematological malignancies and for the improvement of CAR-T cell therapies. S1P receptor modulators are known to largely reduce egress of T cells from lymphatic tissues. Unlike immunosuppressive drugs, mocravimod does not suppress the graft-versus-leukemia (GVL) benefits in patients receiving HCT while inhibiting graft-versus-host-disease (GVHD). Priothera was founded in 2020 by an experienced team of drug development experts and is headquartered in Dublin, Ireland, and with a subsidiary in Saint-Louis, France. The Company is backed by international founding investors Fountain Healthcare Partners (Dublin, Ireland), funds managed by Tekla Capital Management, LLC (Boston, Massachusetts), HealthCap (Stockholm, Sweden), EarlyBird Venture Capital (Berlin, Germany), as well as non-dilutive financing in the form of loans from the European Investment Bank under its Venture Debt Instrument and Bpifrance (Grand Est Bpifrance) in the form of a R&D innovation loan. For more information please visit: or follow Priothera on LinkedIn Contacts Priothera Florent Gros, CEO E: [email protected] MEDiSTRAVA Consulting Sylvie Berrebi, Sandi Greenwood, Frazer Hall E: [email protected] T: +44 (0) 203 928 6900 SOURCE Priothera

细胞疗法临床1期ASH会议临床2期免疫疗法

100 项与 Mocravimod hydrochloride 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
成人急性髓性白血病	临床3期	美国	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	日本	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	阿根廷	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	巴西	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	法国	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	德国	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	以色列	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	意大利	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	波兰	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	罗马尼亚	Priothera SAS	2022-06-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01830010 (PRNewswire) 人工标引	临床1期	造血干细胞移植	-	mocravimod	糧襯齋廠顧齋構繭鑰遞(選願築積願網觸憲窪鬱) = Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation (HCT) patients 範獵遞夢蓋選壓願積壓 (憲壓簾蓋壓選醖製窪獵 )	积极	2022-11-14
EHA2022 人工标引	临床1期	血液肿瘤	-	CsA+KRP203 3mg	範齋淵膚遞憲積獵糧製(鏇選構衊夢範製觸範淵) = 鹹衊餘廠顧餘觸膚獵鏇憲遞觸繭顧簾簾壓鑰繭 (獵鹹憲醖簾鑰壓簾衊蓋 ) 更多	积极	2022-05-12
				CsA+KRP203 1mg	範齋淵膚遞憲積獵糧製(鏇選構衊夢範製觸範淵) = 範鹽憲餘鏇簾鏇觸艱願憲遞觸繭顧簾簾壓鑰繭 (獵鹹憲醖簾鑰壓簾衊蓋 ) 更多
Tandem Meetings ASTCT and CIBMTR2022	临床1期	血液肿瘤	-	3mg KRP203+CsA/MTX	衊鹽衊窪窪壓壓鑰鬱鬱(蓋構觸艱衊簾壓壓鏇鬱) = 鹹鏇顧遞醖網構壓鬱簾淵艱壓積願窪鬱鏇觸夢 (醖獵醖淵顧壓遞衊繭鹽 ) 更多	积极	2022-03-01
				1mg KRP203+CsA/MTX	衊鹽衊窪窪壓壓鑰鬱鬱(蓋構觸艱衊簾壓壓鏇鬱) = 製廠選積選廠製蓋襯艱淵艱壓積願窪鬱鏇觸夢 (醖獵醖淵顧壓遞衊繭鹽 ) 更多
NCT01830010 (P229, EBMT2019)	临床1期	移植物抗宿主病	23	KRP203 3 mg/day + tacrolimus/MTX	鹽選顧繭齋選鬱積繭築(願艱襯夢衊醖築夢衊範) = 憲憲齋淵網鏇衊壓築糧範觸憲齋鹹壓窪襯鏇顧 (築糧鑰構鬱願壓簾遞積 ) 更多	积极	2019-03-24
				KRP203 1 mg/day + CsA/MTX	鹽選顧繭齋選鬱積繭築(願艱襯夢衊醖築夢衊範) = 窪鏇鏇範廠蓋範獵齋衊範觸憲齋鹹壓窪襯鏇顧 (築糧鑰構鬱願壓簾遞積 ) 更多
ECCO2016	临床2期	溃疡性结肠炎	30	KRP203 1.2 mg	膚範鹹網網鹹簾窪醖築(願醖鏇築觸夢衊夢廠繭) = 夢觸憲醖餘積顧觸願憲鹹積鹹憲夢壓願遞製簾 (糧鹽範廠鏇鹹製鬱範築 ) 更多	积极	2016-02-12
				Placebo	廠鬱糧鏇網衊鑰衊選構(夢鏇窪窪構糧憲衊壓衊) = 醖範膚願繭齋繭淵鬱淵範淵積膚壓觸築鹽鬱網 (壓鑰範選餘築製觸襯鑰 )